Scholarlink

Introduction <p>In recent years, the role and utility of real-world evidence in complementing randomized controlled trials in oncology has become increasingly evident, accompanied by ongoing progress in real-world data (RWD) capabilities. Beyond Western regions such as North America and Europe, RWD in the broader international landscape has similarly matured, but is comparatively not as well characterized.</p> Methods <p>Recognizing a need to better understand contemporary availability and characteristics of oncology RWD sources outside North America and Europe, a targeted literature review was conducted, focused on English language articles published from January 1, 2020 to May 1, 2025. The review encompassed select representative countries from Latin America (LATAM), Middle East and North Africa (MENA), and Asia Pacific (APAC).</p> Results <p>Of the 466 publications ultimately included in review, data extraction yielded 103 unique oncology RWD sources (61 in LATAM, 9 in MENA, 33 in APAC). Across the regions, similarities and differences were observed. While some countries like Brazil and Taiwan demonstrate potential impact of government-led initiatives across the entire health system, other countries like Argentina and Mexico rely more on site-level or network/consortium approaches for data collection and analysis. Overall, a common trend was seen in emerging examples of progress towards advanced RWD capabilities such as biobanks or clinicogenomic datasets.</p> Conclusion <p>Looking ahead, continued investment and coordinated, multi-stakeholder effort will be critical to fully realize potential of oncology RWD in these regions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploration of Real-World Data Sources in Latin America, Middle East and North Africa, and Asia Pacific, to Support Oncology Evidence Generation: A Targeted Literature Review and Regional Recommendations

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月28日

查看全文
  • Shouki Bazarbashi,
  • Alexander Chiu,
  • Nancy Dreyer,
  • Chirag Ghai,
  • Alexandra Guarin,
  • Soo Chin Lee,
  • Fernando Petracci,
  • Gustavo Werutsky,
  • Cameron Wong,
  • Manmohan Singh

摘要

Introduction

In recent years, the role and utility of real-world evidence in complementing randomized controlled trials in oncology has become increasingly evident, accompanied by ongoing progress in real-world data (RWD) capabilities. Beyond Western regions such as North America and Europe, RWD in the broader international landscape has similarly matured, but is comparatively not as well characterized.

Methods

Recognizing a need to better understand contemporary availability and characteristics of oncology RWD sources outside North America and Europe, a targeted literature review was conducted, focused on English language articles published from January 1, 2020 to May 1, 2025. The review encompassed select representative countries from Latin America (LATAM), Middle East and North Africa (MENA), and Asia Pacific (APAC).

Results

Of the 466 publications ultimately included in review, data extraction yielded 103 unique oncology RWD sources (61 in LATAM, 9 in MENA, 33 in APAC). Across the regions, similarities and differences were observed. While some countries like Brazil and Taiwan demonstrate potential impact of government-led initiatives across the entire health system, other countries like Argentina and Mexico rely more on site-level or network/consortium approaches for data collection and analysis. Overall, a common trend was seen in emerging examples of progress towards advanced RWD capabilities such as biobanks or clinicogenomic datasets.

Conclusion

Looking ahead, continued investment and coordinated, multi-stakeholder effort will be critical to fully realize potential of oncology RWD in these regions.